帕利哌酮缓释片结合丁螺环酮对难治性精神分裂症患者疗效及安全性评价

Efficacy and safety of paliperidone extended-release tablets combined withbuspirone in patients with refractory schizophrenia

目的:研究帕利哌酮缓释片+丁螺环酮治疗难治性精神分裂症患者的疗效。方法:选难治性精神分裂症患者72例,随机分组治疗,对照组采用帕利哌酮缓释片治疗;研究组服用帕利哌酮缓释片结合丁螺环酮治疗。比较临床疗效。结果:研究组治疗总有效率、PANSS总分、不良反应率均显著优于对照组,差异显著(P<0.05)。两组阴阳因子的总分减分率,研究组和对照组相似,P>0.05。结论:将帕利哌酮缓释片+丁螺环酮用于难治性精神分裂症患者中,其疗效提高,安全性提高,可用于临床用药。

Objective:To study the efficacy of paliperidone sustained-release tablets+buspirone in the treatment of patients with refractory schizophrenia.Methods:72 patients with refractory schizophrenia were randomly divided into two groups:the control group was treated with paliperidone sustained-release tablets.The research group was treated with paliperidone sustained-release tablets combined with buspirone.Compare clinical efficacy.Results:The total effective rate,total score of PANSS and adverse reaction rate of the research group were significantly better than those of the control group,the difference was significant(P<0.05).The total score of yin and yang factors in the two groups was similar,and the test group and the control group were similar,P>0.05.Conclusion:Paclitaxel sustained-release tablets+buspirone is used in patients with refractory schizophrenia.Its efficacy is improved and its safety is improved.It can be used for clinical use.